CAJ | 학술논문

目的：探讨孟鲁司特钠对小儿支气管哮喘患者肺功能和气道炎症的改善作用。方法选取我院收治的小儿支气管哮喘患者108例，依据病情将患者均分为研究组和对照组；研究组给予常规治疗加用孟鲁司特钠，对照组给予常规治疗。比较两组患儿治疗前和治疗后肺功能(FEV1、FEV1/FVC和FEV1占预计值)检查、气道炎症因子(IL-5、IL-10和TNF-α)水平变化、嗜酸性粒细胞计数和临床疗效等。结果治疗后研究组的FEV1、FEV1/FVC和FEV1占预计值等指标与对照组相比均具有统计学意义(P<0.05)。治疗后研究组患儿的IL-5、IL-10和TNF-α与对照组相比有统计学意义(P<0.05)。治疗后研究组EOS%为(4.29±1.03)%，与对照组(5.98±1.25)%相比差异有统计学意义(P<0.05)。79.6%的研究组患儿支气管哮喘得到显效治疗，与对照组(29.6%)相比差异有统计学意义(P<0.05)。结论孟鲁司特钠能有效改善小儿支气管哮喘患者的肺功能和气道炎症，值得临床推广使用。
목적：탐토맹로사특납대소인지기관효천환자폐공능화기도염증적개선작용。방법선취아원수치적소인지기관효천환자108례，의거병정장환자균분위연구조화대조조；연구조급여상규치료가용맹로사특납，대조조급여상규치료。비교량조환인치료전화치료후폐공능(FEV1、FEV1/FVC화FEV1점예계치)검사、기도염증인자(IL-5、IL-10화TNF-α)수평변화、기산성립세포계수화림상료효등。결과치료후연구조적FEV1、FEV1/FVC화FEV1점예계치등지표여대조조상비균구유통계학의의(P<0.05)。치료후연구조환인적IL-5、IL-10화TNF-α여대조조상비유통계학의의(P<0.05)。치료후연구조EOS%위(4.29±1.03)%，여대조조(5.98±1.25)%상비차이유통계학의의(P<0.05)。79.6%적연구조환인지기관효천득도현효치료，여대조조(29.6%)상비차이유통계학의의(P<0.05)。결론맹로사특납능유효개선소인지기관효천환자적폐공능화기도염증，치득림상추엄사용。
Objective To explore the effects of montelukast for improving pulmonary functions and airway inflammation in children patients with bronchial asthma. Methods A total of 108 children patients with bronchial asthma who were admitted to our hospital were assigned to research group and control group based on their disease conditions. The re-search group was given regular treatment and montelukast, and the control group was given regular treatment alone. Ex-amination of pulmonary functions (FEV1, FEV1/FVC and ratio of FEV1 to predicting value), changes of airway inflamma-tion factors (IL-5, IL-10 and TNF-α), eosnophils count and clinical effects before and after the treatment between the two groups of children patients were assessed. Results The differences of indices such as FEV1, FEV1/FVC and ratio of FEV1 to predicting value in the research group after the treatment were all statistically significant compared with those in the control group(P<0.05). The differences of IL-5, IL-10 and TNF-α in the research group after the treat-ment were statistically significant compared with those in the control group (P<0.05). EOS% was (4.29±1.03)% in the research group after the treatment, and the difference was statistically significant compared with that of (5.98±1.25)%in the control group (P<0.05). 79.6%of patients in the research group received an effective treatment of bronchial asthma, and the difference was statistically significant compared with that of 29.6% in the control group (P<0.05). Con-clusion Montelukast is effective in improving pulmonary functions and airway inflammation in children patients with bronchial asthma, which is worthy of clinical promotion and application.